Data from the ongoing ALLELE study consistent with prior efficacy and safety findings for tabelecleucel in treatment of Relapsed/Refractory (R/R) EBV+ PTLD in hematopoietic cell transplant (HCT) and ...
Enrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating tabelecleucel in patients with EBV+PTLD in Solid Organ Transplant and Allogeneic Hematopoietic Cell Transplant after ...
Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results